Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors …
Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …
Roche’s checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of metastatic breast cancer, a milestone …
Sandia National Laboratories materials chemist Dale Huber has been working on the challenge of making iron-based nanoparticles the exact same size for 15 years. Now, …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
